argenx SE (NASDAQ:ARGX) Given Consensus Recommendation of “Moderate Buy” by Analysts

argenx SE (NASDAQ:ARGX) has been assigned a consensus recommendation of “Moderate Buy” from the twenty-three brokerages that are currently covering the company, Marketbeat.com reports. Three equities research analysts have rated the stock with a hold recommendation, nineteen have issued a buy recommendation and one has assigned a strong buy recommendation to the company. The average twelve-month price objective among brokerages that have issued a report on the stock in the last year is $630.42.

A number of equities research analysts have recently commented on the stock. Barclays raised shares of argenx from an “equal weight” rating to an “overweight” rating in a research note on Tuesday, August 6th. JMP Securities increased their price target on argenx from $497.00 to $606.00 and gave the stock a “market outperform” rating in a report on Friday, November 1st. Piper Sandler raised their target price on argenx from $553.00 to $620.00 and gave the stock an “overweight” rating in a research note on Friday, November 1st. JPMorgan Chase & Co. boosted their price target on argenx from $640.00 to $670.00 and gave the company an “overweight” rating in a research note on Monday, November 4th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $617.00 price objective on shares of argenx in a research report on Wednesday, November 20th.

Institutional Trading of argenx

Several institutional investors have recently made changes to their positions in ARGX. FMR LLC grew its position in argenx by 35.9% in the 3rd quarter. FMR LLC now owns 4,793,472 shares of the company’s stock worth $2,598,445,000 after purchasing an additional 1,265,486 shares in the last quarter. Janus Henderson Group PLC boosted its stake in shares of argenx by 0.4% in the 3rd quarter. Janus Henderson Group PLC now owns 2,479,207 shares of the company’s stock worth $1,343,797,000 after buying an additional 10,975 shares during the last quarter. Clearbridge Investments LLC grew its holdings in shares of argenx by 3.6% in the second quarter. Clearbridge Investments LLC now owns 617,466 shares of the company’s stock valued at $265,535,000 after acquiring an additional 21,189 shares in the last quarter. Wellington Management Group LLP increased its position in shares of argenx by 13.0% during the third quarter. Wellington Management Group LLP now owns 482,346 shares of the company’s stock valued at $261,470,000 after acquiring an additional 55,617 shares during the last quarter. Finally, Sei Investments Co. lifted its holdings in argenx by 15.2% during the second quarter. Sei Investments Co. now owns 381,544 shares of the company’s stock worth $164,079,000 after acquiring an additional 50,477 shares during the period. Institutional investors own 60.32% of the company’s stock.

argenx Stock Up 0.2 %

NASDAQ ARGX opened at $617.49 on Thursday. The company has a market capitalization of $37.28 billion, a price-to-earnings ratio of -701.69 and a beta of 0.61. argenx has a twelve month low of $327.73 and a twelve month high of $622.32. The stock has a fifty day simple moving average of $565.73 and a 200 day simple moving average of $498.07.

argenx (NASDAQ:ARGX) last issued its quarterly earnings data on Thursday, October 31st. The company reported $1.39 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.10 by $1.29. The company had revenue of $588.88 million during the quarter, compared to the consensus estimate of $543.29 million. argenx had a negative return on equity of 1.45% and a negative net margin of 2.11%. During the same period last year, the company earned ($1.25) earnings per share. Research analysts expect that argenx will post 2.2 earnings per share for the current fiscal year.

About argenx

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren’s syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.